An interventional study of FH diagnosis program and Implementation strategy package: Develop and implement tools for quality monitoring in Familial Hypercholesterolemia, sponsored by Geisinger Clinic. Enrolling by invitation at 1 site in United States. Open to participants aged 26 Years and older. Per ClinicalTrials.gov, last updated 2025-12-22.
Sponsored by Geisinger Clinic · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Hyperlipoproteinemia Type II with a site in United States — 17 open to participants now, 18 under way, 6 of them phase 3. Hyperlipoproteinemia Type II · United States.
Among the 76 studies in Hyperlipoproteinemia Type II with a site in United States, this one is the 11th largest by planned enrollment of the 68 interventional ones that give a count, is one of 6 that started in 2022, is one of 13 with no phase, reaches primary completion later than 4 of the 17 other live ones, and was the 52nd registered.
251 studies on the registry are indexed under Hyperlipoproteinemia Type II; 57 are open to participants now.
Browse Hyperlipoproteinemia Type II studies →17 of the 76 studies in Hyperlipoproteinemia Type II with a site in United States are open now. Recruiting first, the newest first:
Arrowhead Pharmaceuticals · Sites in United States, Denmark, Poland
Ages 12–17
University of Wisconsin, Madison · Sites in United States
Ages 18+
Merck Sharp & Dohme LLC · Sites in United States, Australia, Belgium and 17 more countries
Ages 6–17
Brigham and Women's Hospital · Sites in United States
Novartis Pharmaceuticals · Sites in United States, Austria, China and 8 more countries
Ages 2–11
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 37 Hyperlipoproteinemia Type II studies recruiting now, 17 (46%) set no upper age limit and 16 (43%) stop at 75 or younger; 17 take children under 18; 6 take healthy volunteers.
This study: 26 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 18 · Phase 3 34 · Phase 4 4
First in 1985; this study’s year is marked. 6 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 532 is above the median of 131 across 180 interventional studies indexed under Hyperlipoproteinemia Type II.
Median enrollment 163 across the 68 interventional studies, 22 across the 8 observational. Of the 57 that completed or were terminated, 32 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 76 have an industry lead sponsor. The 10 most frequent:
Geisinger Clinic is the lead sponsor of 127 studies on the registry; 17 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 7 (78%) have results posted.
Geisinger Clinic has 3 studies filed under Hyperlipoproteinemia Type II — fewer than ten, so there is no comparison to draw.
6 of the studies in Hyperlipoproteinemia Type II with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05284513Geisinger ClinicCollaborative Approach to Reach Everyone With Familial Hypercholesterolemia (CARE-FH) | 2027-01 |
| NCT05750667Northwestern UniversityPenn Family Screening for Familial Hypercholesterolemia | 2027-02-28 |
| NCT07919353Northwestern UniversityPenn Family Screening for Familial Hypercholesterolemia (NHLBI R33) Trial 3 | 2027-02-28 |
| NCT06743659Brigham and Women's HospitalComputerized Decision Support for Identification and Management of Familial Hypercholesterolemia | 2027-03-30 |
| NCT06439654Atlantic Health SystemAtlantic Lipid Lowering Treatment Optimization Program | 2027-05-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 76 studies in Hyperlipoproteinemia Type II with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Diagnosis rates of familial hypercholesterolemia (FH) are low in the United States, despite multiple guidelines and recommendations for screening and treatment of high cholesterol, to prevent heart attacks in those affected. Using a stepped-wedge design, the investigators plan to utilize tools from implementation science to improve uptake, acceptability, and sustainability of FH diagnostic programs in primary care settings. If successful, this study will provide tools generalizable to other health care systems to improve FH diagnosis rates.
Familial hypercholesterolemia (FH) is a common genetic disorder (prevalence 1 in 250) that requires lifelong sustained medical care. Evidence-based guidelines for screening and treatment for FH exist. These include universal screening of children ages 9-11, of adolescents ages 18-20, and of adults ages 40 and above; approved diagnostic tools including lipid panels and genetic testing; and recommendations for initiation of lipid lowering medication. FH diagnosis is currently made too late in life, often after a premature heart attack has occurred creating a care gap that results in excess cardiovascular morbidity and mortality. Diagnosing FH in the primary care setting would optimize treatment for individuals with FH and close this care gap. Utilizing tools from implementation science and human centered design, and by considering uptake, acceptability, and sustainability of programs related to FH care should improve earlier diagnosis. Implementation strategies that include insights from patients, clinicians, and healthcare systems are necessary. The long-term goal is to create an effective FH diagnosis program that is practical and sustainable in the real-world setting. The main objective of this project is to determine the uptake of an FH diagnosis program integrated into primary care practices to promote early identification of adult and pediatric patients that is generalizable to other healthcare settings. The research question is, does using a multi-level implementation strategy package, designed to address the specific needs of patients, clinicians, and healthcare systems, improve the diagnosis and activation of care management for individuals with FH. The specific aims are to: 1) to design a clinical trial to assess multi-level implementation strategies for improving FH diagnosis in an integrated health system, 2) compare FH diagnosis rates among primary care clinicians who receive the implementation strategy package versus those who do not, 3) to measure implementation success of an organized FH diagnosis program, and 4) to explore patient-related service and health outcomes related to an FH diagnosis program.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Phased rollout to clinic sites across the the Geisinger system using stepped wedge design
Behavioral: FH diagnosis program · Behavioral: Implementation strategy package: Develop and implement tools for quality monitoring · Behavioral: Implementation strategy package: Develop educational materials · Behavioral: Implementation strategy package: Conduct educational outreach visits · Behavioral: Implementation strategy package: Intervene with clinicians and patients to enhance · Behavioral: Behavioral (e.g., Psychotherapy, Lifestyle Counseling) Implementation strategy package: Identify and prepare champions Clinical lipid champions · Behavioral: Implementation strategy package: Audit and provide feedback · Behavioral: Implementation strategy package: Stage implementation scale up
Phased rollout to clinic sites across the the Geisinger system using stepped wedge design
Behavioral: FH diagnosis program · Behavioral: Implementation strategy package: Develop and implement tools for quality monitoring · Behavioral: Implementation strategy package: Develop educational materials · Behavioral: Implementation strategy package: Conduct educational outreach visits · Behavioral: Implementation strategy package: Intervene with clinicians and patients to enhance · Behavioral: Behavioral (e.g., Psychotherapy, Lifestyle Counseling) Implementation strategy package: Identify and prepare champions Clinical lipid champions · Behavioral: Implementation strategy package: Audit and provide feedback · Behavioral: Implementation strategy package: Stage implementation scale up
Phased rollout to clinic sites across the the Geisinger system using stepped wedge design
Behavioral: FH diagnosis program · Behavioral: Implementation strategy package: Develop and implement tools for quality monitoring · Behavioral: Implementation strategy package: Develop educational materials · Behavioral: Implementation strategy package: Conduct educational outreach visits · Behavioral: Implementation strategy package: Intervene with clinicians and patients to enhance · Behavioral: Behavioral (e.g., Psychotherapy, Lifestyle Counseling) Implementation strategy package: Identify and prepare champions Clinical lipid champions · Behavioral: Implementation strategy package: Audit and provide feedback · Behavioral: Implementation strategy package: Stage implementation scale up
Phased rollout to clinic sites across the the Geisinger system using stepped wedge design
Behavioral: FH diagnosis program · Behavioral: Implementation strategy package: Develop and implement tools for quality monitoring · Behavioral: Implementation strategy package: Develop educational materials · Behavioral: Implementation strategy package: Conduct educational outreach visits · Behavioral: Implementation strategy package: Intervene with clinicians and patients to enhance · Behavioral: Behavioral (e.g., Psychotherapy, Lifestyle Counseling) Implementation strategy package: Identify and prepare champions Clinical lipid champions · Behavioral: Implementation strategy package: Audit and provide feedback · Behavioral: Implementation strategy package: Stage implementation scale up
Phased rollout to clinic sites across the the Geisinger system using stepped wedge design
Behavioral: FH diagnosis program · Behavioral: Implementation strategy package: Develop and implement tools for quality monitoring · Behavioral: Implementation strategy package: Develop educational materials · Behavioral: Implementation strategy package: Conduct educational outreach visits · Behavioral: Implementation strategy package: Intervene with clinicians and patients to enhance · Behavioral: Behavioral (e.g., Psychotherapy, Lifestyle Counseling) Implementation strategy package: Identify and prepare champions Clinical lipid champions · Behavioral: Implementation strategy package: Audit and provide feedback · Behavioral: Implementation strategy package: Stage implementation scale up
Uptake of screening, diagnosis, and initiation of care management for FH
EHR tools to order labs, record results, and document FH care
Education regarding guidelines for identification and treatment of FH
Continuing medical education (CME) material for FH that is presented to
Notify patients simultaneously with clinicians about the need for screening
Clinical lipid champions
Provide aggregate level feedback to clinics on diagnosing FH
Develop the timeline for the stepped-wedge rollout to primary care
FH diagnosis rate (Aim 2)
FH diagnosis rate, is achieving both the scheduling of a clinic visit and evidence the clinician, at that visit, has completed evidence-based FH diagnostic evaluation, defined as completing one of: using the FH clinic note to document care, adding FH diagnosis on the problem list, using the FH smart-set (or ordered a genetic test for FH), making a referral to the lipid clinic, or starting a statin for an evidence-based indication
Time frame: Up to 45 months
Acceptability (Aim 3)
Clinician and patient satisfaction and self-efficacy with the FH diagnosis program
Time frame: Month 9, 12, 18, 24, 30, 36, 42
Timeliness (Aim 4)
Time to FH screen, time to diagnostic evaluation, time to statin initiation
Time frame: Up to 45 months
Initiation medication use (Aim 2)
Initiation of lipid lowering medication by healthcare clinician
Time frame: Up to 45 months
Lipid measurement (Aim 2)
Order of a lipid panel
Time frame: Up to 45 months
Genetic testing (Aim 2)
Order of a genetic test for FH
Time frame: Month 9, 12, 18, 24, 30, 36, 42
Problem list diagnosis of FH (Aim 2)
Clinician adds diagnosis of FH to the patients problem list in the electronic health record
Time frame: Up to 45 months
FH smartset (Aim 2)
Clinician uses and completes all field of the FH smartset
Time frame: Month 9, 12, 18, 24, 30, 36, 42
Best Practice Alert (Aim 2)
Clinician adheres to and acts on recommendation in the Best Practice Alert
Time frame: Up to 45 months
FH Clinic Note (Aim 2)
Clinician completes the FH clinic note
Time frame: Up to 45 months
Fidelity (Aim 3)
Documentation of adaptations to the FH diagnosis program
Time frame: Up to 45 months
Cost (Aim 3)
Cost to implement the implementation strategy package
Time frame: Up to 45 months
Function (Aim 4)
Return of genetic result to patient (if ordered and patient undergoes testing)
Time frame: Up to 45 months
Function (Aim 4)
Reduction in lipid level from baseline to end of the study period
Time frame: Up to 45 months
Function (Aim 4)
Patient side effects to medications
Time frame: Up to 45 months
Plan to share: No — Available upon request from PIs
Started Sep 2022 (actual). Primary completion is estimated for Jan 2027, 52 months after the start.
Of 37 non-industry interventional studies with no phase under Hyperlipoproteinemia Type II, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 51. This study's planned 52 months is above that.
Counting every sponsor, half of 39 studies reached it within 29 months; a quarter within 12 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hyperlipoproteinemia Type II →